Metagenomi, Inc.
MGX
$1.56
-$0.05-2.81%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -43.88% | -39.62% | -4.22% | 16.84% | 45.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -43.88% | -39.62% | -4.22% | 16.84% | 45.13% |
| Cost of Revenue | -13.25% | -12.83% | -2.68% | 15.65% | 30.77% |
| Gross Profit | -17.05% | -14.22% | 1.43% | -14.58% | -19.12% |
| SG&A Expenses | -17.38% | -13.77% | -3.41% | 11.00% | 20.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.19% | -13.04% | -2.84% | 14.56% | 28.16% |
| Operating Income | -4.29% | -3.76% | 2.12% | -13.26% | -19.46% |
| Income Before Tax | -19.20% | -23.23% | -16.69% | -38.76% | -31.50% |
| Income Tax Expenses | 17.67% | -283.04% | -192.88% | -168.68% | -125.69% |
| Earnings from Continuing Operations | -19.99% | -16.16% | -0.88% | -14.36% | -16.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.99% | -16.16% | -0.88% | -14.36% | -16.30% |
| EBIT | -4.29% | -3.76% | 2.12% | -13.26% | -19.46% |
| EBITDA | -4.16% | -3.29% | 3.24% | -12.40% | -18.47% |
| EPS Basic | 68.86% | 81.88% | 85.17% | 85.24% | 53.26% |
| Normalized Basic EPS | 68.30% | 81.86% | 84.76% | 84.30% | 54.63% |
| EPS Diluted | 68.86% | 81.88% | 85.17% | 85.24% | 53.26% |
| Normalized Diluted EPS | 68.30% | 81.86% | 84.76% | 84.30% | 54.63% |
| Average Basic Shares Outstanding | 51.97% | 129.58% | 305.40% | 604.84% | 423.59% |
| Average Diluted Shares Outstanding | 51.97% | 129.58% | 305.40% | 604.84% | 423.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |